CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
- Written by PR Newswire
SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for...
Read more: CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA